What is it about?
Clinical effectiveness Cost benefit analysis of universal versus targeted screening for MRSA upon admission to hospitals. Comparison of two hospitals' results. Cost benefit (overall costs) and clinical effectiveness (as measured by hospital-acquired MRSA) analyses did not support universal screening.
Featured Image
Why is it important?
Targeted screening of high risk patients for MRSA is cost effective as compared to universal screening upon admission to hospitals.
Read the Original
This page is a summary of: Clinical Effectiveness and Cost Benefit of Universal versus Targeted Methicillin-Resistant Staphylococcus aureus Screening upon Admission in Hospitals, Infection Control and Hospital Epidemiology, August 2011, Cambridge University Press,
DOI: 10.1086/660875.
You can read the full text:
Contributors
The following have contributed to this page
